Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyclomethycaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.98 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.98 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.98 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 13/20 | 0.48 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.47 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclomethycaine SCHEMBL634210 | 1.00 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL25345 | 0.99 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL25346 | 0.99 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL634093 | 0.95 | SCN1A (0.92) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Cyclomethycaine SCHEMBL634094 | 0.95 | SCN1A (0.92) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL503030 | 0.84 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL503032 | 0.84 | SCN1A (0.98) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL25713 | 0.83 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL25714 | 0.83 | SCN1A (1.00) | SCN1ASCN2ASCN3AHRH3CYP2D6 | |
| Piperocaine SCHEMBL9224611 | 0.81 | SCN1A (0.95) | SCN1ASCN2ASCN3AHRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217080-B2 | Anti-infective methods and systems for treating pathogen-induced disordered tissues | CHURCH & DWIGHT CO., INC. | 2012-07-10 | — | — | US | claimed |
| US-20110245784-A1 | ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | claimed |
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2968228-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | Quadex Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | QUADEX PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC | 2015-12-03 | — | — | US | disclosed |
| US-9125911-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2014160369-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-8217080-B2 | Anti-infective methods and systems for treating pathogen-induced disordered tissues | CHURCH & DWIGHT CO., INC. | 2012-07-10 | — | — | US | disclosed |
| US-6423750-B1 | LIQUID CONTAINING PENETRATION ADJUVANT | CHURCH & DWIGHT CO., INC. | 2002-07-23 | — | — | US | disclosed |
| US-6420431-B1 | TOPICALLY APPLYING QUATERNARY AMMONIUM COMPOUND (SUCH AS BENZALKONIUM CHLORIDE) TO COLD SORE AND RUBBING; COMPOUND PENETRATES SKIN WITHOUT DIFFUSION; QUICK RELIEF | CHURCH & DWIGHT CO., INC. | 2002-07-16 | — | — | US | disclosed |
| US-6414032-B1 | CONTAINING PENETRATION INTENSIFIER AND ANTIINFECTIVE AGENTS; TOPICAL APPLYING | CHURCH & DWIGHT CO., INC. | 2002-07-02 | — | — | US | disclosed |
| US-6410599-B1 | MIXTURE OF BENZALKONIUM CHLORIDE, WATER AND ISOPROPANOL | CHURCH & DWIGHT CO., INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1214064-A1 | SYSTEMS FOR AGITATED DELIVERY OF ANTI-INFECTIVE COMPOSITIONS TO TREAT DISORDERED TISSUE SUCH AS COLD SORES | Johnson, B. Ron (US) | 2002-06-19 | — | — | EP | disclosed |
| US-6211243-B1 | APPLYING AND AGITATION THEN PENETRATION FOR COLD SORES | CHURCH & DWIGHT CO., INC. | 2001-04-03 | — | — | US | disclosed |
| WO-2001021171-A1 | SYSTEMS FOR AGITATED DELIVERY OF ANTI-INFECTIVE COMPOSITIONS TO TREAT DISORDERED TISSUE SUCH AS COLD SORES | JOHNSON B RON (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001020981-A2 | ANTI-INFECTIVE COMPOSITIONS FOR TREATING DISORDERED TISSUE SUCH AS COLD SORES | JOHNSON B RON (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001021170-A1 | SYSTEMS FOR DELIVERING ANTI-INFECTIVE COMPOSITIONS FROM FRANGIBLE AMPULES TO TREAT DISORDERED TISSUE SUCH AS COLD SORES | JOHNSON B RON (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | SAMHD1, DCTD, NT5E | SCN1A 938/4885SCN2A 992/4885SCN3A 1012/4885 |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | NT5E, SAMHD1, DCTD | SCN1A 538/4885SCN2A 577/4885SCN3A 634/4885 |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | SAMHD1, CUTA, TK1 | SCN1A 349/4885SCN2A 348/4885SCN3A 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.